These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 27492833)

  • 1. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.
    Vogelmeier C; Paggiaro PL; Dorca J; Sliwinski P; Mallet M; Kirsten AM; Beier J; Seoane B; Segarra RM; Leselbaum A
    Eur Respir J; 2016 Oct; 48(4):1030-1039. PubMed ID: 27492833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
    D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
    Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
    Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).
    Bateman ED; Chapman KR; Singh D; D'Urzo AD; Molins E; Leselbaum A; Gil EG
    Respir Res; 2015 Aug; 16(1):92. PubMed ID: 26233481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study.
    Singh D; Jones PW; Bateman ED; Korn S; Serra C; Molins E; Caracta C; Gil EG; Leselbaum A
    BMC Pulm Med; 2014 Nov; 14():178. PubMed ID: 25404569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.
    Donohue JF; Soong W; Wu X; Shrestha P; Lei A
    Respir Med; 2016 Jul; 116():41-8. PubMed ID: 27296819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison.
    Medic G; Lindner L; van der Weijden M; Karabis A
    Adv Ther; 2016 Mar; 33(3):379-99. PubMed ID: 26883661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.
    Miravitlles M; Chapman KR; Chuecos F; Ribera A; Gil EG
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2041-53. PubMed ID: 27621610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
    Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
    Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial.
    Płoszczuk A; Bosheva M; Spooner K; McIver T; Dissanayake S
    Ther Adv Respir Dis; 2018; 12():1753466618777924. PubMed ID: 29857783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.
    D'Urzo AD; Singh D; Donohue JF; Kerwin EM; Ribera A; Molins E; Chuecos F; Jarreta D; Gil EG
    Int J Chron Obstruct Pulmon Dis; 2019; 14():479-491. PubMed ID: 30880938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.
    Rabe KF; Timmer W; Sagkriotis A; Viel K
    Chest; 2008 Aug; 134(2):255-262. PubMed ID: 18403672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
    Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
    Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD.
    Singh D; Nicolini G; Bindi E; Corradi M; Guastalla D; Kampschulte J; Pierzchała W; Sayiner A; Szilasi M; Terzano C; Vestbo J;
    BMC Pulm Med; 2014 Mar; 14():43. PubMed ID: 24621109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
    Kerwin EM; D'Urzo AD; Gelb AF; Lakkis H; Garcia Gil E; Caracta CF;
    COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of indacaterol in patients with chronic obstructive pulmonary disease aged over 65 years: A pooled analysis.
    Girodet PO; Jasnot JY; Le Gros V; Decuypère L; Cao W; Devouassoux G
    Respir Med; 2017 Jul; 128():92-101. PubMed ID: 28566230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease.
    D'Urzo A; Rennard S; Kerwin E; Donohue JF; Lei A; Molins E; Leselbaum A
    Respir Med; 2017 Apr; 125():39-48. PubMed ID: 28340861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.